Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.09
HSIC's Cash to Debt is ranked lower than
95% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.57 vs. HSIC: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
HSIC' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.37 Max: 1.76
Current: 0.09
0.07
1.76
Equity to Asset 0.44
HSIC's Equity to Asset is ranked higher than
58% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.40 vs. HSIC: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
HSIC' s Equity to Asset Range Over the Past 10 Years
Min: 0.43  Med: 0.49 Max: 0.64
Current: 0.44
0.43
0.64
Interest Coverage 28.22
HSIC's Interest Coverage is ranked higher than
59% of the 34 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.22 vs. HSIC: 28.22 )
Ranked among companies with meaningful Interest Coverage only.
HSIC' s Interest Coverage Range Over the Past 10 Years
Min: 11.01  Med: 19.51 Max: 29.73
Current: 28.22
11.01
29.73
F-Score: 6
Z-Score: 5.00
M-Score: -2.52
WACC vs ROIC
9.18%
14.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 6.90
HSIC's Operating margin (%) is ranked higher than
66% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.96 vs. HSIC: 6.90 )
Ranked among companies with meaningful Operating margin (%) only.
HSIC' s Operating margin (%) Range Over the Past 10 Years
Min: 6.02  Med: 6.90 Max: 7.1
Current: 6.9
6.02
7.1
Net-margin (%) 4.51
HSIC's Net-margin (%) is ranked higher than
66% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.85 vs. HSIC: 4.51 )
Ranked among companies with meaningful Net-margin (%) only.
HSIC' s Net-margin (%) Range Over the Past 10 Years
Min: 3.24  Med: 4.34 Max: 4.76
Current: 4.51
3.24
4.76
ROE (%) 16.83
HSIC's ROE (%) is ranked higher than
70% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.13 vs. HSIC: 16.83 )
Ranked among companies with meaningful ROE (%) only.
HSIC' s ROE (%) Range Over the Past 10 Years
Min: 12.04  Med: 15.28 Max: 16.82
Current: 16.83
12.04
16.82
ROA (%) 7.71
HSIC's ROA (%) is ranked higher than
80% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.55 vs. HSIC: 7.71 )
Ranked among companies with meaningful ROA (%) only.
HSIC' s ROA (%) Range Over the Past 10 Years
Min: 5.99  Med: 7.74 Max: 8.37
Current: 7.71
5.99
8.37
ROC (Joel Greenblatt) (%) 44.77
HSIC's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 23.26 vs. HSIC: 44.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSIC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 41.4  Med: 48.65 Max: 51.27
Current: 44.77
41.4
51.27
Revenue Growth (3Y)(%) 8.30
HSIC's Revenue Growth (3Y)(%) is ranked higher than
61% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.90 vs. HSIC: 8.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSIC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.5  Med: 9.60 Max: 34.8
Current: 8.3
4.5
34.8
EBITDA Growth (3Y)(%) 8.30
HSIC's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 34 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.70 vs. HSIC: 8.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSIC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.3  Med: 12.10 Max: 89.5
Current: 8.3
8.3
89.5
EPS Growth (3Y)(%) 9.60
HSIC's EPS Growth (3Y)(%) is ranked higher than
59% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.80 vs. HSIC: 9.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HSIC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.3  Med: 12.05 Max: 70.4
Current: 9.6
6.3
70.4
» HSIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

HSIC Guru Trades in Q1 2015

Columbia Wanger 391,800 sh (-0.25%)
Ron Baron 408,263 sh (-0.30%)
Ken Fisher 530,109 sh (-0.66%)
Mario Gabelli 200,180 sh (-1.31%)
Jeremy Grantham 259,382 sh (-2.36%)
Paul Tudor Jones 6,200 sh (-4.62%)
» More
Q2 2015

HSIC Guru Trades in Q2 2015

Columbia Wanger 423,034 sh (+7.97%)
Paul Tudor Jones Sold Out
Ken Fisher 528,144 sh (-0.37%)
Ron Baron 402,842 sh (-1.33%)
Mario Gabelli 195,242 sh (-2.47%)
Jeremy Grantham 227,346 sh (-12.35%)
» More
Q3 2015

HSIC Guru Trades in Q3 2015

Ray Dalio 7,235 sh (New)
Jim Simons 94,096 sh (New)
Ron Baron 394,521 sh (-2.07%)
Ken Fisher 514,663 sh (-2.55%)
Mario Gabelli 183,742 sh (-5.89%)
Columbia Wanger 383,034 sh (-9.46%)
Jeremy Grantham 185,258 sh (-18.51%)
» More
Q4 2015

HSIC Guru Trades in Q4 2015

Ray Dalio Sold Out
Jim Simons Sold Out
Columbia Wanger Sold Out
Mario Gabelli 182,992 sh (-0.41%)
Ken Fisher 502,002 sh (-2.46%)
Jeremy Grantham 151,358 sh (-18.30%)
» More
» Details

Insider Trades

Latest Guru Trades with HSIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.90
HSIC's P/E(ttm) is ranked lower than
71% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.52 vs. HSIC: 27.90 )
Ranked among companies with meaningful P/E(ttm) only.
HSIC' s P/E(ttm) Range Over the Past 10 Years
Min: 12.02  Med: 22.44 Max: 35.14
Current: 27.9
12.02
35.14
Forward P/E 21.69
HSIC's Forward P/E is ranked lower than
88% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.19 vs. HSIC: 21.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.90
HSIC's PE(NRI) is ranked lower than
64% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.65 vs. HSIC: 27.90 )
Ranked among companies with meaningful PE(NRI) only.
HSIC' s PE(NRI) Range Over the Past 10 Years
Min: 12.02  Med: 22.02 Max: 32.13
Current: 27.9
12.02
32.13
P/B 4.54
HSIC's P/B is ranked lower than
99.99% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.93 vs. HSIC: 4.54 )
Ranked among companies with meaningful P/B only.
HSIC' s P/B Range Over the Past 10 Years
Min: 1.57  Med: 2.99 Max: 4.54
Current: 4.54
1.57
4.54
P/S 1.26
HSIC's P/S is ranked lower than
79% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.34 vs. HSIC: 1.26 )
Ranked among companies with meaningful P/S only.
HSIC' s P/S Range Over the Past 10 Years
Min: 0.48  Med: 0.86 Max: 1.27
Current: 1.26
0.48
1.27
PFCF 26.02
HSIC's PFCF is ranked lower than
78% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.10 vs. HSIC: 26.02 )
Ranked among companies with meaningful PFCF only.
HSIC' s PFCF Range Over the Past 10 Years
Min: 9.28  Med: 19.20 Max: 34.11
Current: 26.02
9.28
34.11
POCF 22.75
HSIC's POCF is ranked lower than
65% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.12 vs. HSIC: 22.75 )
Ranked among companies with meaningful POCF only.
HSIC' s POCF Range Over the Past 10 Years
Min: 8.08  Med: 16.08 Max: 23.59
Current: 22.75
8.08
23.59
EV-to-EBIT 18.44
HSIC's EV-to-EBIT is ranked lower than
67% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.95 vs. HSIC: 18.44 )
Ranked among companies with meaningful EV-to-EBIT only.
HSIC' s EV-to-EBIT Range Over the Past 10 Years
Min: 6  Med: 12.40 Max: 19.9
Current: 18.44
6
19.9
EV-to-EBITDA 15.20
HSIC's EV-to-EBITDA is ranked lower than
81% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.14 vs. HSIC: 15.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.2  Med: 10.60 Max: 15.7
Current: 15.2
5.2
15.7
PEG 2.88
HSIC's PEG is ranked lower than
65% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.47 vs. HSIC: 2.88 )
Ranked among companies with meaningful PEG only.
HSIC' s PEG Range Over the Past 10 Years
Min: 0.56  Med: 2.05 Max: 3.28
Current: 2.88
0.56
3.28
Shiller P/E 39.95
HSIC's Shiller P/E is ranked lower than
69% of the 26 Companies
in the Global Medical Distribution industry.

( Industry Median: 26.83 vs. HSIC: 39.95 )
Ranked among companies with meaningful Shiller P/E only.
HSIC' s Shiller P/E Range Over the Past 10 Years
Min: 20.75  Med: 33.36 Max: 51.46
Current: 39.95
20.75
51.46
Current Ratio 1.50
HSIC's Current Ratio is ranked higher than
59% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.49 vs. HSIC: 1.50 )
Ranked among companies with meaningful Current Ratio only.
HSIC' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 2.06 Max: 2.53
Current: 1.5
1.5
2.53
Quick Ratio 0.80
HSIC's Quick Ratio is ranked lower than
68% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.04 vs. HSIC: 0.80 )
Ranked among companies with meaningful Quick Ratio only.
HSIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.33 Max: 1.66
Current: 0.8
0.8
1.66
Days Inventory 65.88
HSIC's Days Inventory is ranked lower than
59% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 52.54 vs. HSIC: 65.88 )
Ranked among companies with meaningful Days Inventory only.
HSIC' s Days Inventory Range Over the Past 10 Years
Min: 54.28  Med: 58.07 Max: 67.99
Current: 65.88
54.28
67.99
Days Sales Outstanding 42.23
HSIC's Days Sales Outstanding is ranked higher than
67% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 56.51 vs. HSIC: 42.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.01  Med: 41.72 Max: 44.11
Current: 42.23
38.01
44.11
Days Payable 48.19
HSIC's Days Payable is ranked lower than
78% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 74.19 vs. HSIC: 48.19 )
Ranked among companies with meaningful Days Payable only.
HSIC' s Days Payable Range Over the Past 10 Years
Min: 37.11  Med: 42.20 Max: 48.19
Current: 48.19
37.11
48.19

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 34.12
HSIC's Price/Tangible Book is ranked lower than
98% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.27 vs. HSIC: 34.12 )
Ranked among companies with meaningful Price/Tangible Book only.
HSIC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.37  Med: 6.67 Max: 40.04
Current: 34.12
2.37
40.04
Price/Projected FCF 1.55
HSIC's Price/Projected FCF is ranked lower than
73% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.29 vs. HSIC: 1.55 )
Ranked among companies with meaningful Price/Projected FCF only.
HSIC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.37 Max: 14.92
Current: 1.55
0.78
14.92
Price/DCF (Earnings Based) 1.61
HSIC's Price/DCF (Earnings Based) is ranked lower than
54% of the 13 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.06 vs. HSIC: 1.61 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.47
HSIC's Price/Median PS Value is ranked lower than
96% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.15 vs. HSIC: 1.47 )
Ranked among companies with meaningful Price/Median PS Value only.
HSIC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 0.93 Max: 1.46
Current: 1.47
0.28
1.46
Price/Peter Lynch Fair Value 2.85
HSIC's Price/Peter Lynch Fair Value is ranked lower than
88% of the 24 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.19 vs. HSIC: 2.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
HSIC' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.63  Med: 1.62 Max: 2.9
Current: 2.85
0.63
2.9
Price/Graham Number 6.50
HSIC's Price/Graham Number is ranked lower than
95% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.55 vs. HSIC: 6.50 )
Ranked among companies with meaningful Price/Graham Number only.
HSIC' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 2.82 Max: 6.68
Current: 6.5
1.09
6.68
Earnings Yield (Greenblatt) (%) 5.40
HSIC's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.10 vs. HSIC: 5.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSIC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5  Med: 8.00 Max: 16.7
Current: 5.4
5
16.7
Forward Rate of Return (Yacktman) (%) 13.47
HSIC's Forward Rate of Return (Yacktman) (%) is ranked higher than
52% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.68 vs. HSIC: 13.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSIC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 10.4  Med: 15.55 Max: 28.6
Current: 13.47
10.4
28.6

More Statistics

Revenue(Mil) $10630
EPS $ 5.69
Beta1.06
Short Percentage of Float3.73%
52-Week Range $126.17 - 161.62
Shares Outstanding(Mil)81.94

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 11,199 11,720 12,178
EPS($) 6.62 7.33 8.25
EPS without NRI($) 6.62 7.33 8.25

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:ABC, MCK, CAH, SHTDF, PDCO » details
Traded in other countries:HS2.Germany,
Henry Schein Inc was incorporated in Delaware in December 1992. The Company is engaged in offering a selection of products and services and value-added solutions for operating efficient practices and delivering high quality care. The Company operates through a centralized and automated distribution network with a selection of more than 96,000 branded products and Henry Schein private brand products in stock, as well as more than 110,000 additional products available as special order items. It also offers its customers technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. The Company conducts its business through two reportable segments: health care distribution and technology and value-added services. The health care distribution reportable segment aggregates its dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Company's technology and value-added services group provides software, technology and other value-added services to health care practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. The Company's value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The Company's main competitors include the GACD Group, Pluradent AG & Co., Lifco AB, Planmeca Oy, Billericay Dental Supply Co. Ltd., National Veterinary Services and Alcyon SA. The Company's business is subject to local, state, federal and foreign governmental laws and regulations applicable to the distribution of pharmaceuticals and medical devices. The Company's businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially hazardous substances, and safe working conditions. Its businesses are also subject to requirements of similar and other foreign governmental laws and regulations affecting its operations abroad.
» More Articles for NAS:HSIC

Headlines

Articles On GuruFocus.com
The Best Companies of the Medical Industry – September 2015 Sep 25 2015 
The Case for Investing in AmerisourceBergen Aug 13 2015 
Weekly 52-Week Highs Highlight: BCS, RYAAY, MMC, HSIC Jun 14 2015 
Why Hedge Funds Are Betting On AmerisourceBergen Apr 10 2015 
Weekly 52-Week Highs Highlight: DLTR, NTES, HSIC, ADM Nov 23 2014 
AmerisourceBergen Is a Center Piece in the Pharma Industry Sep 30 2014 
Weekly 52-Week Highs Highlight: IHG, HSIC, GGP, AAL Jun 02 2014 
Mario Gabelli on Aging America, Alcohol, Twitter, Facebook Dec 17 2013 
Importance of Leadership in a 5-Star Company Feb 05 2013 
Looking at the Big Picture Apr 25 2012 

More From Other Websites
Henry Schein Rides High on Acquisitions amid Currency Woes Feb 12 2016
Henry Schein, Inc. Earnings Analysis: 2015 By the Numbers Feb 11 2016
Henry Schein (HSIC) Shows Strength: Stock Rises 6.2% Feb 11 2016
Edited Transcript of HSIC earnings conference call or presentation 10-Feb-16 3:00pm GMT Feb 10 2016
Henry Schein (HSIC) Tops Q4 Earnings on Strong Revenues Feb 10 2016
Henry Schein Inc Earnings Call scheduled for 10:00 am ET today Feb 10 2016
Henry Schein (HSIC) Tops Q4 Earnings, Revenue Estimates Feb 10 2016
HENRY SCHEIN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 10 2016
Henry Schein tops Street 4Q forecasts Feb 10 2016
Henry Schein tops Street 4Q forecasts Feb 10 2016
Q4 2015 Henry Schein Inc Earnings Release - Before Market Open Feb 10 2016
Henry Schein Reports Record Fourth Quarter And Full Year Results Feb 10 2016
Will Henry Schein (HSIC) Surprise Q4 Earnings Estimates? Feb 08 2016
Henry Schein And Supplier Partners Join Together To Expand Access To Oral Health Care For 300,000... Feb 05 2016
Henry Schein To Acquire A Majority Interest In Brazil's Dental Cremer Feb 05 2016
Henry Schein Completes Acquisition Of RxWorks Feb 03 2016
Henry Schein, Inc. – Value Analysis (NASDAQ:HSIC) : February 2, 2016 Feb 02 2016
Henry Schein, Inc. breached its 50 day moving average in a Bullish Manner : February 2, 2016 Feb 02 2016
Henry Schein to Present at Two Investor Conferences in February Jan 28 2016
Henry Schein to Present at Two Investor Conferences in February Jan 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK